Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
Revenue (TTM)
$-- Mln
Net Profit (TTM)
$-- Mln
ROE
-0.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.4
Industry P/E
--
EV/EBITDA
1.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
10,828,300
CFO
$-44.27 Mln
EBITDA
$-46.71 Mln
Net Profit
$-43.52 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Scisparc (SPRC)
| -18.1 | 4.3 | -36.8 | -75.8 | -83.2 | -- | -- |
|
BSE Sensex
| 4.3 | 3.9 | 7.7 | 10.3 | 14.5 | 21.5 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
|---|---|
|
Scisparc (SPRC)
| -75.2 |
|
S&P Small-Cap 600
| 13.9 |
|
BSE Sensex
| 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Scisparc (SPRC)
|
0.3 | 3.3 | 1.3 | -6.3 | -- | -79.7 | -- | 0.4 |
| 6.8 | 400.2 | 161.0 | 14.5 | 9.4 | 5.7 | 24.8 | 1.6 | |
| 19.9 | 221.3 | 20.2 | -30.2 | -145.4 | -96.3 | -- | 7.1 | |
| 1.9 | 3.6 | 0.0 | -14.6 | -- | -321.9 | -- | 2.0 | |
| 2.8 | 28.6 | 0.0 | -29.0 | -- | -1038.7 | -- | 3.6 |
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the... treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. Address: Tower A, Tel Aviv, Israel, 6971916 Read more
CEO & CFO
Mr. Oz Adler CPA
President & Director
Mr. Itschak Shrem
Headquarters
Tel Aviv
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Scisparc Ltd (SPRC) stood at $ 10 Mln as on 31-Dec-24
The share price of Scisparc Ltd (SPRC) is $0.29 (NASDAQ) as of 21-May-2025 16:16 EDT. Scisparc Ltd (SPRC) has given a return of -83.22% in the last 3 years.
Scisparc Ltd (SPRC) has a market capitalisation of $ 3 Mln as on 20-May-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Scisparc Ltd (SPRC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Scisparc Ltd (SPRC) and enter the required number of quantities and click on buy to purchase the shares of Scisparc Ltd (SPRC).
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. Address: Tower A, Tel Aviv, Israel, 6971916
The CEO & director of Mr. Oz Adler CPA. is Scisparc Ltd (SPRC), and CFO & Sr. VP is Mr. Itschak Shrem.
There is no promoter pledging in Scisparc Ltd (SPRC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
35
|
|
|
19
|
|
|
2
|
|
|
0
|
|
|
35
|
|
|
19
|
|
|
2
|
|
|
0
|
| Scisparc Ltd (SPRC) | Ratios |
|---|---|
|
Return on equity(%)
|
-79.71
|
|
Operating margin(%)
|
-570.9
|
|
Net Margin(%)
|
-481.16
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Scisparc Ltd (SPRC) was No Profit.
$-0.03
(
